Shares of Avenue Therapeutics plunged in trading after the company announced the U.S. Food and Drug Administration rejected the New Drug Application for intravenous tramadol over safety concerns.
The U.S. Food and Drug Administration approved Trevena’s Olinvyk as a new intravenous opioid for short-term management of acute pain in a hospital setting.
Privately held pharmaceutical company Wraser Pharmaceuticals announced the publication of a White Paper addressing opioid safety.
Specialty pharmaceutical company AcelRx Pharmaceuticals Inc. announced the resubmission of the New Drug Application (NDA) for DSUVIA with the U.S. FDA.
